EVE.S
Latest Trade
0.20CHFChange
-0.00(-0.50%)Volume
304,701Today's Range
-
0.2052 Week Range
-
0.37As of on the SIX Swiss Exchange ∙ Minimum 15 minute delay
Previous Close | 0.20 |
|---|---|
Open | 0.20 |
Volume | 304,701 |
3M AVG Volume | 45.05 |
Today's High | 0.20 |
Today's Low | 0.20 |
52 Week High | 0.37 |
52 Week Low | 0.20 |
Shares Out (MIL) | 911.73 |
Market Cap (MIL) | 185.38 |
Forward P/E | -6.78 |
Dividend (Yield %) | -- |
Evolva Appoints Carsten Däweritz As CFO
Evolva Says CFO Leaves For Personal Reasons
Evolva Turns To FY Gross Loss Of CHF 1.9 Mln
Evolva Holding SA (Evolva) is a Switzerland-based biotechnology company reseaching, developing and commerzializing nature-based ingrendients. The activity of the Company is divided into two segments: technololgy platforms - combines biology with technology to produce nature-based ingredients; technology servises- provides tailored services to clients across industries. The Company is focused on developing and increase the yield and efficiency of the production of various ingredients.
Industry
Business Services
Executive Leadership
Oliver Walker
Chief Executive Officer
Andre Pennartz
Chief Financial Officer
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 24.58 |
Price To Book (MRQ) | 1.11 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 6.22 |
LT Debt To Equity (MRQ) | 2.88 |
Return on Investment (TTM) | -18.02 |
Return on Equity (TTM) | -16.64 |
* UPON COMPLETION OF PUBLIC NOTICE PERIOD, COMPANY EXPECTS EPA TO COMPLETE REGISTRATION OF NOOTKATONE QUICKLY THEREAFTER Source text for Eikon: Further company coverage: (Gdansk Newsroom)
* SIGNS A CHF 12 MILLION INVESTMENT WITH SWISS COMPANY NICE & GREEN TO FUND FUTURE GROWTH
* EVOLVA HOLDING SA - STANDBY EQUITY DISTRIBUTION AGREEMENT ENTERED INTO IN 2017 WITH YORKVILLE ADVISORS WILL EXPIRE ON APRIL 1, 2020 Source text for Eikon: Further company coverage:
* EVOLVA - ENTERS NEW AGREEMENT WITH INTERNATIONAL FLAVORS & FRAGRANCES
* PROPOSES TO CREATE AUTHORIZED CAPITAL IN AMOUNT OF A MAXIMUM OF CHF 32,875,129.40
* FULL YEAR REVENUE INCREASED TO CHF 11.6 MILLION IN 2019 (+30%) MAINLY DRIVEN BY PRODUCT-RELATED REVENUES GROWING BY 59% TO CHF 5.5 MILLION
* ANNOUNCES CHANGES TO BOARD OF DIRECTORS AND MANAGEMENT TEAM TO SUPPORT DELIVERY OF STRATEGIC PRIORITIES
* EVOLVA WILL PROPOSE TO REDUCE OVERALL NUMBER OF BOARD MEMBERS FROM FIVE TO FOUR AT NEXT ANNUAL GENERAL MEETING Source text: https://bit.ly/2XRCnNu Further company coverage: (Gdansk Newsroom)
* PRODUCT REVENUES REACHED CHF 3.0 MILLION IN FIRST HALF OF 2019 (+65%)
* STUART STRATHDEE TO RETIRE FROM BOARD OF DIRECTORS OF EVOLVA Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* EVOLVA RECEIVES A NOTICE FROM US EPA ON ITS NEXT-GENERATION ACTIVE INGREDIENT AGAINST TICKS AND MOSQUITOES
* CASH POSITION OF CHF 60.4 MILLION ON 31 DECEMBER 2018 (31 DECEMBER 2017: CHF 97.2M) Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* FOR FULL YEAR 2018, WE EXPECT PRODUCT SALES TO GROW AT A HIGH DOUBLE DIGIT PERCENTAGE RATE.
* PRODUCT SALES DOUBLED, REACHING CHF 1.8 MILLION IN THE FIRST HALF OF 2018
* EVOLVA ANNOUNCES OLIVER WALKER TO SUCCEED SIMON WADDINGTON AS CEO
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.